Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses

Last update: Oct 29, 2026

Details

Location: EU 27
Contracting Authority: Horizon Europe (2021 - 2027)
Contracting Authority Type: Development Institution
Status: Open
Budget: EUR 37,300,000
Award ceiling: 10,000,000
Award floor: 9,000,000
Sector: Health, Research & Innovation
Eligible applicants: Unrestricted / Unspecified
Eligible nationalities: Afghanistan, Albania, Algeria, Angola, Argentina, Armenia, Aruba, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Central African Republic, Chad, Colombia, Comoros, Congo, Costa Rica, Cote d'Ivoire, Croatia, Cuba, Curaçao, Cyprus, Czech Republic, Dem. Rep. Congo, Denmark, Djibouti, Dominica, Commonwealth of, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini (Swaziland), Ethiopia, Faroe Islands, Fiji, Finland, France, French Polynesia, French Southern Territory, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Greenland, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nepal, Netherlands, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, North Macedonia, Norway, Pakistan, Palau, Palestine / West Bank & Gaza, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Romania, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Serbia, Sierra Leone, Sint Maarten, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Spain, Sri Lanka, St. Pierre and Miquelon, Sudan, Suriname, Sweden, Switzerland, Syria, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Tunisia, Türkiye, Turkmenistan, Tuvalu, Uganda, UK, Ukraine, Uzbekistan, Vanuatu, Venezuela, Vietnam, Wallis and Futuna, Yemen, Zambia, Zimbabwe
Date posted: Dec 12, 2025

Quick Summary

Objectives: 

Objectives

  • Purpose: Support research to advance existing monoclonal antibody candidates for prevention and treatment of one targeted virus only...
Eligibility criteria: 
  • Eligible applicants: Any legal entity may participate, including public or private bodies, international organisations and entities from non-associated third countries, subject to the topic rules. Beneficiaries and affiliated entities must register in the Participant Register and obtain a PIC before grant signature.
  • Geographic and legal eligibility: Legal entities established in the United States are eligible to receive Union funding. Legal entities established in China are not el...
Share

Similar grants

By Locations
Funding Agency: NGO
Status: open
Location: Ireland, UK
Funding Agency: EC
Status: open
Location: Cyprus
By Sectors
Funding Agency: Government
Status: open
Location: Norway
Funding Agency: NPO
Status: open
Location: UK